Drugs / Tirzepatide
Tirzepatide
Drug FDA approvedMarketed as Mounjaro, Zepbound
Dual GIP receptor and GLP-1 receptor agonist·First approved·2023·2 brands
- Registered trials
- 203
- Ongoing
- 128/ 63%
- Completed
- 71
- Indications
- 3
Approved indications by brand
Indications below are grouped by brand, since each brand carries its own label.
| Brand | Indication |
|---|---|
| Mounjaro | Type 2 diabetes mellitus (adjunct to diet and exercise) |
| Zepbound | Chronic weight management in adults with obesity or overweight with at least one weight-related comorbid condition |
| Moderate to severe obstructive sleep apnea in adults with obesity |
Clinical trial landscape
203 registered studies reference this molecule or one of its brands. The split below shows how many are ongoing versus completed per phase.
| Phase | Total | Ongoing | Completed | Split |
|---|---|---|---|---|
| Phase 2 | 59 | 47 | 10 | |
| Phase 3 | 44 | 17 | 27 | |
| Phase 4 | 34 | 30 | 3 | |
| Phase 1 | 27 | 6 | 21 | |
| Unknown | 18 | 7 | 10 | |
| Not applicable | 8 | 8 | 0 | |
| Early Phase 1 | 6 | 6 | 0 | |
| Phase 1/2 | 4 | 4 | 0 | |
| Phase 2/3 | 3 | 3 | 0 | |
| All phases | 203 | 128 | 71 |
Ongoing Completed Balance withdrawn, terminated, or status unreported.
Study records: ClinicalTrials.gov →
Mechanism of action
Activates both GIP and GLP-1 receptors; lowers body weight through reduced caloric intake and appetite, with effects on gastric emptying and adiposity.
Recent developments
Headlines link to the original publisher. Sources limited to a reviewed list of journals, regulators, and medical press.